Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01550614
Other study ID # CT-3-002
Secondary ID
Status Terminated
Phase Phase 3
First received February 29, 2012
Last updated September 27, 2016
Start date March 2012

Study information

Verified date September 2016
Source Cardium Therapeutics
Contact n/a
Is FDA regulated No
Health authority Russia: Ministry of Health of the Russian Federation
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient symptoms, and quality of life. Short-term (8 weeks) and long-term (12 month) safety of Ad5FGF-4 will also be evaluated. The primary endpoint is change in adenosine triphosphate (ATP) stress SPECT reperfusion defect size.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients 18-75 years of age, inclusive

- Postmenopausal female patients, women of childbearing potential and men willing to use an effective contraception method while on the study treatment and/or who agree not to become pregnant or make their partner pregnant throughout the study and during one year after administration of the study drug

- Female subjects of childbearing potential who have a negative urine pregnancy test, and are willing to use an acceptable form of birth control during the study

- Diagnostic coronary angiogram in the past confirming the presence of coronary artery disease. Patients with extensive disease, or high risk for intervention, or who don't want the higher risk angioplasty or surgery, or have had angioplasty with recurrent angina and vessels are not ideal for angioplasty are ideal candidates

- Stable angina pectoris being treated with chronic anti-anginal medication(s) at a stable dose for 2 weeks prior to randomization

- Left ventricular ejection fraction (LVEF) of =30%. If the LVEF is <30% the patient can be enrolled if there is no recent or current congestive heart failure present

- Evidence of stress induced myocardial ischemia by ATP technetium-99m sestamibi SPECT, defined as a reversible perfusion defect size of =9%

- Willing and able to comply with the study requirements

- Provided written informed consent

Exclusion Criteria:

- Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study and one year after administration of the study drug. Women of child bearing potential who are not using an acceptable method of birth control. Women of child bearing potential with a positive urine pregnancy test within 24 hours prior to the start of investigational product

- Patients with unstable angina for whom an immediate revascularization procedure is indicated

- Patients for whom a cardiac revascularization procedure is planned in the next 3 months

- Myocardial infarction within the 3 months prior to the Screening visit

- Congestive heart failure NYHA Class IV

- Myocarditis or restrictive pericarditis

- Left main coronary stenosis =70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses =70% in all major coronary conduit vessels (coronary arteries and bypass grafts)

- A single patent coronary conduit (for example, totally occluded RCA and LCx with no bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)

- Clinically significant aortic or mitral valvular heart disease.

- Life threatening coronary ostial stenosis that precludes adequate catheter engagement in any target vessel, unless the vessel can be accessed via a patent bypass graft

- Coronary artery to venous communications, which bypass the coronary capillary bed

- Untreated life-threatening ventricular arrhythmias

- Uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic pressure >100 mm Hg

- CABG surgery within the past 6 months, unless those grafts are now occluded

- Percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months, unless the stented/dilated vessel(s) are now occluded

- Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations

- Transmyocardial or percutaneous myocardial laser revascularization within the previous year

- Prior treatment with any cardiovascular gene therapy

- Patients who received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Genetic:
Alferminogene tadenovec
One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)

Locations

Country Name City State
Russian Federation Municipal Hospital #15 Moscow

Sponsors (2)

Lead Sponsor Collaborator
Cardium Therapeutics Advanced Biosciences Research

Country where clinical trial is conducted

Russian Federation, 

References & Publications (3)

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002 Mar 19;105(11):1291-7. — View Citation

Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N; Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003 Oct 15;42(8):1339-47. — View Citation

Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, Engler RL. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. Epub 2007 Aug 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in reversible perfusion defect size (RPDS) as measured by adenosine triphosphate (ATP) single-photon emission computed tomography with technetium-99m sestamibi (SPECT) Baseline and Week 8 No
Secondary Change in angina frequency and nitroglycerin use Baseline and Week 8 No
Secondary Change in quality of life using the Seattle Angina Questionnaire Baseline and Week 8 No
Secondary Change in patient functional class using CCS anginal classification Baseline and Week 8 No
Secondary Safety of Ad5FGF-4 as assessed by adverse events and clinical laboratory testing Through Week 8 Yes
Secondary Long-term safety of Ad5FGF-4 as assessed by serious adverse events Through Month 12 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Recruiting NCT02870764 - The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris Phase 4
Completed NCT04648306 - Restore EF Observational Study
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Not yet recruiting NCT02280850 - Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina Phase 4
Completed NCT04785846 - Registry of RESOLUTE-ONYX™ Zotarolimus-eluting Stent Utilization in Percutaneous Small Vessel Coronary Interventionism.
Completed NCT03759067 - Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients N/A
Not yet recruiting NCT03306550 - Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin N/A
Completed NCT03193294 - CORonary MICrovascular Angina (CorMicA) N/A
Completed NCT04131816 - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program N/A
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Recruiting NCT03783351 - Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) N/A
Recruiting NCT06464042 - Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease
Not yet recruiting NCT05857904 - Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain N/A
Recruiting NCT01838148 - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia
Terminated NCT02914834 - Acupuncture for Individuals With Stable Angina N/A
Recruiting NCT05825339 - Absolute Flow for Ischemia With No Obstructive Coronary Arteries
Completed NCT05804500 - RecoveryPlus Telerehab Platform Pilot Study N/A
Completed NCT03518645 - Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds N/A
Recruiting NCT05056662 - Post-Revascularization Optimization and PHysiological Evaluation of intermediaTe Lesions